Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Impact of D-Dimer Assays Performed at Local Labs Vs. Central Laboratory in the Evaluation of Apex Trial Outcomes

Lisa K. Jennings, PhD, Jayaprakash Kotha, PhD MBBS, Mason Dixon, BS, Alexander Cohen, MD, John T Curnutte, MD PhD

Blood (2017) 130 (Supplement 1): 2391.

https://doi.org/10.1182/blood.V130.Suppl_1.2391.2391

Published: 2017

Journal Articles

Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma

Arnold Bolomsky, PhD, Roy Heusschen, PhD, Karin Schlangen, PhD, Kathrin Schönfelder, MSc, Joséphine Muller, MSc, Wolfgang Schreiner, PhD, Niklas Zojer, MD, Jo Caers, Heinz Ludwig, MD

Blood (2016) 128 (22): 309.

https://doi.org/10.1182/blood.V128.22.309.309

Published: 2016

Journal Articles

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Alexander T Cohen, MBBS MSc MD, Rim Halaby, MD, Serge Korjian, MD, Yazan Daaboul, MD, Donald Szlosek, Douglas Arbetter, MPH, Samuel Z. Goldhaber, MD, Russell Hull, MBBS, Adrian Hernandez, MD, Alexander Gold, MD, Brian Wiens, PhD, Robert Harrington, MD, C. Michael Gibson, MD

Blood (2016) 128 (22): 3824.

https://doi.org/10.1182/blood.V128.22.3824.3824

Published: 2016

Journal Articles

Maternal Embryonic Leucine Zipper Kinase (MELK): a Novel Marker of Poor Prognosis and Attractive Drug Target in High-Risk Patients with Multiple Myeloma

Arnold Bolomsky, Karin Schlangen, Artur Köhler, Goran Mitulovic, Wolfgang Schreiner, Niklas Zojer, MD, Heinz Ludwig

Blood (2015) 126 (23): 1823.

https://doi.org/10.1182/blood.V126.23.1823.1823

Published: 2015

Journal Articles

RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response

Isabel JF Hofman, Mark van Duin, PhD, George Mulligan, PhD, Ellen Geerdens, Emanuela Garelli, Cecilia Mancini, Heidi Lemmens, Michel Delforge, Peter Vandenberghe, MDPhD, Iwona Wlodarska, Anna Aspesi, Lucienne Michaux, Pieter Sonneveld, MD PhD, Kim De Keersmaecker

Blood (2015) 126 (23): 2969.

https://doi.org/10.1182/blood.V126.23.2969.2969

Published: 2015

Journal Articles

Suppression Of Uninvolved Immunoglobulin Has Significant Clinical Implication Including Predicting Relapse In Multiple Myeloma

Saulius Girnius, M.D., Rachel Neuwirth, Ph.D, Dixie-Lee Esseltine, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Munshi C Nikhil, MD

Blood (2013) 122 (21): 3151.

https://doi.org/10.1182/blood.V122.21.3151.3151

Published: 2013

Journal Articles

Description Of The Hematological Toxicity Of Different Regimens Using Bortezomib In Multiple Myeloma (CyborD, Vel-Dex and VMP)

Dominic Duquette, BPharm, MSc, Vincent Laroche, MD,FRCPC

Blood (2013) 122 (21): 5386.

https://doi.org/10.1182/blood.V122.21.5386.5386

Published: 2013

Journal Articles

Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

Athiwat Hutchaleelaha, Ph.D., Christine Ye, Ph.D., Yonghong Song, Ph.D., Todd Lorenz, MD, Daniel Gretler, MD, Joseph L Lambing, Ph.D.

Blood (2012) 120 (21): 2266.

https://doi.org/10.1182/blood.V120.21.2266.2266

Published: 2012

Journal Articles

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Jesús F San Miguel, MD PhD, Paul G. Richardson, MD, Robert Z. Orlowski, MD, PhD, Hartmut Goldschmidt, Deyanira Corzo, MD, Carol Satler, Dixie-Lee Esseltine, MD, FRCPC, Rachel Neuwirth, MS, Maria Ponsillo, MD, Andrew Z Cakana, MD, FRCPath, Jay King, MD, William M Deraedt, PhD, Avinash Desai, Yana Lutska, Dina Gifkins, PhD, Kevin Liu, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 2933.

https://doi.org/10.1182/blood.V118.21.2933.2933

Published: 2011

Journal Articles

International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.

Michel Delforge, MD, PhD, Hadewijch De Samblanx, Hilde Demuynck, Greet Bries, Philippe Mineur, Nathalie Meuleman, Fritz Offner, Chantal Doyen, Walter Feremans, Ann Van de Velde, Christophe Ravoet, Isabelle Vande Broek, Jan Van Droogenbroeck, Gabry Kuijten-Celzo, Joris Diels, Rita Ganguly, Ravinder Dhawan

Blood (2009) 114 (22): 4523.

https://doi.org/10.1182/blood.V114.22.4523.4523

Published: 2009

Journal Articles

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Donna E. Reece, MD, Young Trieu, MSc, Christine Chen, MD, Vishal Kukreti, MD, FRCPC, Wei Xu, PhD, Peter Anglin, MD, Suzanne Trudel, MD

Blood (2009) 114 (22): 1853.

https://doi.org/10.1182/blood.V114.22.1853.1853

Published: 2009

Journal Articles

Ciprofloxacin Inhibits Bortezomib-Mediated Apoptosis in Multiple Myeloma Models in Association with Induction of Heme Oxygenase-1.

Qing Chen, PhD, Dixie-Lee Esseltine, MD, Rachel B. Neuwirth, PhD, Paul G. Richardson, MD, Robert Z. Orlowski, MD, PhD

Blood (2007) 110 (11): 2365.

https://doi.org/10.1182/blood.V110.11.2365.2365

Published: 2007

Journal Articles

Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma: Final Results of a Phase I/II Clinical Trial.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, DipRCPath, Simon Hallam, MRCP, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath

Blood (2007) 110 (11): 2713.

https://doi.org/10.1182/blood.V110.11.2713.2713

Published: 2007

Journal Articles

Response to Bortezomib Therapy for Multiple Myeloma (MM) in Actual Clinical Practice: Preliminary Effectiveness Findings of an International Observational Study.

Michel Delforge, MD, PhD, Eirini Katodritou, MD, PhD, Konstantinos Zervas, MD, PhD, Deniz Sargin, MD, Cyrille Hulin, MD, Mats Linderholm, MD, PhD, Evgenia Verrou, MD, Vicki Poon, MPH, Ravinder Dhawan, PhD

Blood (2007) 110 (11): 4837.

https://doi.org/10.1182/blood.V110.11.4837.4837

Published: 2007

Journal Articles

Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.

Blood (2007) 110 (11): 4843.

https://doi.org/10.1182/blood.V110.11.4843.4843

Published: 2007

Journal Articles

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Blood (2007) 110 (10): 3557–3560.

https://doi.org/10.1182/blood-2006-08-036947

Published: 2007

Includes: Supplemental data

Journal Articles

Ten-Year Overall Survival Analysis of Current Treatments of Relapsed or Refractory Multiple Myeloma in Canada.

Donna Reece, MD, Daniel Grima, MSc, Cheryl Attard, MSc, Kim Yoong, BSc, Phm, Farah Jivraj, MSc

Blood (2006) 108 (11): 5517.

https://doi.org/10.1182/blood.V108.11.5517.5517

Published: 2006

Journal Articles

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.

Ruben Niesvizky, P.G. Richardson, P. Sonneveld, M.W. Schuster, M. Coleman, D. Irwin, E.A. Stadtmauer, T. Facon, J. Harousseau, A. Boral, K.C. Anderson

Blood (2006) 108 (11): 3529.

https://doi.org/10.1182/blood.V108.11.3529.3529

Published: 2006

Journal Articles

Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study.

Asher Alban Chanan-Khan, MD, Pieter Sonneveld, MD, Michael W. Schuster, MD, David Irwin, Edward A. Stadtmauer, MD, Thierry Facon, MD, Jean-Luc Harousseau, MD, Dina Ben-Yehuda, MD, Sagar Lonial, MD, Hartmut Goldschmidt, MD, Donna E. Reece, MD, Rachel B. Neuwirth, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2006) 108 (11): 3535.

https://doi.org/10.1182/blood.V108.11.3535.3535

Published: 2006

Journal Articles

A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, BSc, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath

Blood (2006) 108 (11): 3542.

https://doi.org/10.1182/blood.V108.11.3542.3542

Published: 2006

NARROW

Impact of D-Dimer Assays Performed at Local Labs Vs. Central Laboratory in the Evaluation of Apex Trial Outcomes

Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma

The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Maternal Embryonic Leucine Zipper Kinase (MELK): a Novel Marker of Poor Prognosis and Attractive Drug Target in High-Risk Patients with Multiple Myeloma

RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response

Suppression Of Uninvolved Immunoglobulin Has Significant Clinical Implication Including Predicting Relapse In Multiple Myeloma

Description Of The Hematological Toxicity Of Different Regimens Using Bortezomib In Multiple Myeloma (CyborD, Vel-Dex and VMP)

Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.

Sequencing Novel Agents in Relapsed/Refractory Multiple Myeloma: Use of Bortezomib-Based Therapy After Lenalidomide + Dexamethasone.

Ciprofloxacin Inhibits Bortezomib-Mediated Apoptosis in Multiple Myeloma Models in Association with Induction of Heme Oxygenase-1.

Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma: Final Results of a Phase I/II Clinical Trial.

Response to Bortezomib Therapy for Multiple Myeloma (MM) in Actual Clinical Practice: Preliminary Effectiveness Findings of an International Observational Study.

Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Ten-Year Overall Survival Analysis of Current Treatments of Relapsed or Refractory Multiple Myeloma in Canada.

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.

Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study.

A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only